Compare Gilead Sciences, Inc. (GILD) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Jabil Inc — how do they compare? Gilead Sciences, Inc. trades at $134.8 (market cap $163.51B), while Jabil Inc trades at $308.24 (market cap $33.45B). The key difference: Gilead Sciences, Inc. is far larger — about 4.9× Jabil Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | JBL | |
|---|---|---|
Market Cap | $163.51B | $33.45B |
Sector | Health | Technology |
52-Week High | $155.80 | $385.50 |
52-Week Low | $108.22 | $192.49 |
Enterprise Value | $178.05B | $35.98B |
Dividend Yield | 2.49% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JBL trades at $313.15, down 4.18% today amid bearish technical signals. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.16 vs. $3.10 expected) and robust revenue growth projections ($33.6B in 2026). Analyst sentiment is balanced with 50% buy ratings and a $436.50 consensus price target, representing significant upside potential. Recent developments include expansion of AI manufacturing capacity in India and new logistics hubs, positioning JBL for continued growth in AI infrastructure markets.
JBL presents a compelling investment case driven by AI infrastructure demand and earnings momentum, though valuation concerns and technical weakness warrant caution. The stock's 39.95 P/E ratio appears elevated, but strong ROE (20.62%) and projected profit margin expansion to 2.56% support growth expectations. Key risks include competitive pressures in electronics manufacturing and execution challenges in capacity expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
